Literature DB >> 21265821

Low dose intravenous bevacizumab for the treatment of anaemia in hereditary haemorrhagic telangiectasia.

Patrizia Suppressa1, Suppressa Patrizia, Arcangelo Liso, Liso Arcangelo, Carlo Sabbà, Sabbà Carlo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21265821     DOI： 10.1111/j.1365-2141.2010.08481.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  8 in total

1.  Effects of dilution and prolonged storage with preservative in a polyethylene container on Bevacizumab (Avastin™) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies.

Authors:  Simon Kaja; Jill D Hilgenberg; Eric Everett; Scott E Olitsky; Jim Gossage; Peter Koulen
Journal:  Hum Antibodies       Date:  2011

Review 2.  Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia.

Authors:  Daniela S Ardelean; Michelle Letarte
Journal:  Front Genet       Date:  2015-02-11       Impact factor: 4.599

3.  Hereditary hemorrhagic telangiectasia treated with low dose intravenous bevacizumab.

Authors:  Jee Wan Wee; Young Woo Jeon; Jun Young Eun; Han Jo Kim; Sang Byung Bae; Kyu Taek Lee
Journal:  Blood Res       Date:  2014-09-25

Review 4.  Optimal management of hereditary hemorrhagic telangiectasia.

Authors:  Neetika Garg; Monica Khunger; Arjun Gupta; Nilay Kumar
Journal:  J Blood Med       Date:  2014-10-15

5.  Bevacizumab and gastrointestinal bleeding in hereditary hemorrhagic telangiectasia.

Authors:  George Ou; Cherry Galorport; Robert Enns
Journal:  World J Gastrointest Surg       Date:  2016-12-27

6.  Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.

Authors:  Florian Huemer; Martin Dejaco; Christoph Grabmer; Thomas Melchardt; Daniel Neureiter; Georg Mayer; Alexander Egle; Richard Greil; Lukas Weiss
Journal:  Wien Klin Wochenschr       Date:  2017-02       Impact factor: 1.704

7.  Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia.

Authors:  Andrew B Thompson; Douglas A Ross; Paul Berard; Jaszmin Figueroa-Bodine; Nancy Livada; Sara L Richer
Journal:  Allergy Rhinol (Providence)       Date:  2014-07-15

8.  Bevacizumab as a treatment for hereditary hemorrhagic telangiectasia in children: a case report.

Authors:  Fabio E Ospina; Alex Echeverri; Iván Posso-Osorio; Lina Jaimes; Jaiber Gutierrez; Gabriel J Tobón
Journal:  Colomb Med (Cali)       Date:  2017-06-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.